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Background: Norepinephrine (NE) is one of the primary catecholamines of the sympathetic nervous sys-
tem released during a stress response and plays an important role in modulating immune function. NE
binds to the adrenergic receptors on immune cells, including T cells, resulting in either suppressed or
enhanced function depending on the type of cell, activation status of the cell, duration of NE exposure
and concentration of NE. Here, we aim to analyze the effects of NE on the functionality of naïve (Tn), cen-
tral memory (Tcm) and effector memory (Tem) CD8 T cells.Methods:We isolated CD8 T cell subsets from
healthy human adults and treated cells in vitro with NE (1  106 M) for 16 h; we then stimulated NE
treated and untreated CD8 T cell subsets with antibodies for CD3 and CD28 for 24 and 72 h. We assessed
the level of beta-2 adrenergic receptor (ADRB2) expression in these cells as well as global gene expression
changes in NE treated Tcm cells by microarray analysis. Altered expressed genes after NE treatment were
identiﬁed and further conﬁrmed by RT-qPCR, and by ELISA for protein changes. We further determined
whether the observed NE effects on memory CD8 T cells are mediated by ADRB2 using speciﬁc adrenergic
receptor agonist and antagonists. Finally, we examined the levels of mRNA and protein of the NE-induced
genes in healthy adults with high serum levels of NE (>150 pg/mL) compared to low levels (<150 pg/mL).
Results: We found that memory (Tcm and Tem) CD8 T cells expressed a signiﬁcantly higher level of
ADRB2 compared to naïve cells. Consequently, memory CD8 T cells were signiﬁcantly more sensitive than
naïve cells to NE induced changes in gene expressions in vitro. Global gene expression analysis revealed
that NE induced an elevated expression of inﬂammatory cytokines and chemokines in resting and acti-
vated memory CD8 T cells in addition to a reduced expression of growth-related cytokines. The effects
of NE on memory CD8 T cells were primarily mediated by ADRB2 as conﬁrmed by the adrenergic receptor
agonist and antagonist assays. Finally, individuals with high serum levels of NE had similar elevated gene
expressions observed in vitro compared to the low NE group. Conclusions: Our results demonstrate that
NE preferentially modulates the functions of memory CD8 T cells by inducing inﬂammatory cytokine
production and reducing activation-induced memory CD8 T cell expansion.
Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecom-
mons.org/licenses/by/4.0/).1. Introduction (Elenkov et al., 2000; Kin and Sanders, 2006; Sanders and Straub,A growing body of evidence indicates that the sympathetic
nervous system (SNS) modulates functions of the immune system2002). This nervous-immune communication is illustrated during
a stress response as the SNS releases catecholamines, such as
norepinephrine (NE), which interact with surface receptors on
lymphocytes and modulate their functions (Khan et al., 1986;
Kohm and Sanders, 2000; Sanders, 2012). Chronic stress has detri-
mental effects on the immune system and to some degree resem-
bles the immune changes seen in aging (Gouin et al., 2008; Hu
et al., 2014; Kiecolt-Glaser et al., 1996).
NE is the primary catecholamine released by the SNS and has
been previously found to signiﬁcantly impact lymphocytes, includ-
ing T cells, natural killer (NK) cells and B cells (Kin and Sanders,
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Straub, 2002; Wahle et al., 2006). The effect of NE on immune cells
appears complex as NE can have either a stimulatory or inhibitory
effect depending on the type of immune cell, activation status of
the cell, duration of exposure, and dosage (Kalinichenko et al.,
1999; Kin and Sanders, 2006; Kohm and Sanders, 2001; Levite,
2000). For example, NE simulates the migratory activity of naïve
CD8 T cells but inhibits the migration of activated CD8 T cells
(Strell et al., 2009). Furthermore, NE exposure reduces IL-2 produc-
tion and upregulates chemokine receptors such as CXCR1 and
CXCR2 during CD8 T cell activation (Strell et al., 2009).
CD8 T cells are a heterogeneous population consisting of naïve
(Tn) cells and two major memory cell populations: central memory
(Tcm), which provide a memory reservoir for the rapid response to
stimulation, and effector memory (Tem), which provide immediate
effector functions and protective immunity (Sallusto et al., 2004). It
is unknown if the effect of NE is similar or different across the CD8
T cell subsets (Tn, Tcm and Tem), which may have in different
implications on one’s overall immune function.
NE binds to the adrenergic receptors expressed on the surface of
a variety of immune cells. The beta-2 adrenergic receptor (ADRB2)
is believed to be the primary receptor on T and B cells through
which NE directly modulates cellular activity (Padgett and Glaser,
2003; Sanders, 2012; Sanders et al., 2003; Sanders and Straub,
2002). Signaling through the ADRB2 on lymphocytes is one way
the nervous system regulates the immune system (Nakai et al.,
2014). Previous studies have shown the heterogeneous expression
of the ADRB2 within peripheral blood mononuclear cells (PBMCs)
(Anstead et al., 1998; Khan et al., 1986; Van Tits et al., 1990), as
well as the expression of the ADRB2 on Th1 cells but not on Th2
CD4 T cells (Kohm and Sanders, 2001; Ramer-Quinn et al., 1997;
Sanders, 2012). However, it is unknown whether the expression
of the ADRB2 is also heterogeneous within CD8 T cell subsets
(Tn, Tcm, and Tem), or if NE signals mainly through the ADRB2
on CD8 T cells.
To determine whether NE has a similar or different effect on
CD8 T cell subsets and to identify the speciﬁc changes that occur
in CD8 T cells, we compared the ADRB2 expression on CD8 T cell
subsets (Tn, Tcm and Tem cells) of healthy human donors. In
addition, we examined the consequences of NE exposure on iso-
lated CD8 T cell subsets’ gene expressions and corresponding
protein levels, as well as functional changes. To verify these
changes were a result of NE binding with the ADRB2, we isolated
ADRB2 positive and negative memory CD8 T cells to examine the
impact of NE on cytokine gene expression. We also utilized
adrenergic receptor agonist and antagonists to determine if the
NE effect on gene expression changes in memory CD8 T cells
are mediated by ADRB2. Finally, we examined this phenomenon
in adults with either high or low levels of NE in their serum by
measuring changes in gene expressions and intracellular cyto-
kines of memory CD8 T cells.2. Materials and methods
2.1. Human subjects and blood collection
Peripheral blood was collected at the clinic of the National Insti-
tute on Aging (NIA), National Institutes of Health (NIH) from
healthy adult donors (N = 63) (Supplementary Table 1). PBMCs
were isolated from the blood and used for the experiment immedi-
ately or stored at 80 C for later experimental use. To examine
potential differences in individuals with either high or low levels
of NE, we utilized frozen PBMCs from an investigation at the NIH
Clinical Center examining physiological changes in family
caregivers compared to age-, gender- and ethnicity-matchednormal volunteers (N = 32) (Supplementary Table 2) under an
Internal Review Board approved protocol at the NIH.
2.2. Flow cytometry analysis
For the ADRB2 cell surface staining, freshly isolated PBMCs were
incubated with either an unlabeled monoclonal antibody against
ADRB2 (Abnova) followed by a secondary goat anti-mouse IgG con-
jugated with FITC, or by using the same anti-ADRB2 mAb by cus-
tom conjugation with PerCP/Cy5.5 using a kit (Lightning-Link,
Innova Biosciences) according to the manufacturer’s instructions.
When the secondary goat anti-mouse IgG was used, a non-speciﬁc
mouse IgG was used as a control. Other antibodies used for ﬂow
cytometry staining included CD8a (APC), CD45RA (PE) and CD62L
(FITC) (Biolegend). Samples were analyzed on the BD Accuri™ C6
Flow Cytometer. An example of the ﬂow cytometry staining and
gating strategy can be found in Supplementary Fig. 1.
For intracellular cytokine staining, frozen PBMCs were thawed
and incubated for 3 h in an incubator containing 5% O2. Next,
PMA (50 ng/mL, Sigma), Ionomycin (80 ng/mL, EMD), and a Golgi
Blocker (Monensin, 1 lg/million cells, BD Biosciences) were added
to the cells and incubated for 4 h. Cells were stained with a viabil-
ity dye (e506) and antibodies, including CD8 (PeCy7), CD4 (Paciﬁc
Blue), CD3 (ApcCy7), CD28 (APC), CD45RA (FITC) and isotype
matching control antibodies from Biolegend and ADRB2 (PerCP/
Cy5.5) from Abnova. Cells were washed and then 0.5 ml of ﬁxation
buffer (Biolegend) was added for overnight incubation at 4 C in
the dark. The next day, cells were washed with 1 ml permealiza-
tion buffer (Biolegend). Intracellular staining for IL-1A (PE) and
TNF (PerCP/Cy5.5) from Biolegend were completed in one tube,
and IL-2 (PerCP/Cy5.5, Biolegend) and CCL-2 (PE, eBioscience) in
a separate tube. Isotype and ﬂuorescent dye matched non-speciﬁc
mouse IgG were used as controls for cytokine staining. Samples
were collected on the Canto II Flow Cytometer (BD Biosciences).
Data and mean ﬂuorescent intensity (MFI) were further analyzed
using FloJo V10 software.
We used an antibody against Annexin V and a DNA binding dye,
7-AAD (Biolegend), staining to assess cell death and apoptosis at 24
and 72 h after activation. Samples were analyzed on the BD Accu-
ri™ C6 Flow Cytometer, as previously described.
2.3. Isolation and culture of human CD8 T cell subsets from adults with
NE
The procedure for isolating naïve and memory CD8 T cells was
described previously (Araki et al., 2009). Brieﬂy, PBMCs were iso-
lated by the Ficoll (GE Healthcare) gradient centrifugation. Enrich-
ment of CD8 T cells (naïve and memory) was followed by a
negative immunomagnetic separation process. Brieﬂy, the removal
of other cell types in PBMCs through incubation with a panel of
mouse mAbs including: CD4, CD11b, CD19, CD14, CD16, MHC class
II, erythrocytes, platelets, and CD45RO (for naïve cell enrichment)
or CD45RA (for memory cell enrichment). The antibody bound cells
were subsequently removed by the anti-mouse IgG magnetic
beads (BioMag Goat Anti-Mouse IgG beads, Qiagen). Isolated CD8
T cells were incubated in the presence or absence of 1  106 M
NE (catalog #A7256, Sigma–Aldrich), which was dissolved in PBS
before being immediately added into human culture media
(RPMI1640 with 10% FBS and penicillin (10 U/ml)/streptomycin
(10 lg/mL)) (Life Technologies) for 16 h. A NE concentration of
1  106 M is considered physiologically relevant (Sanders, 2012;
Strell et al., 2009; Torres et al., 2005; Wahle et al., 2006). The next
day, NE-treated or untreated CD8 T cells were further sorted into
naïve (CD45RA+, CD62L+), central memory cells (CD45RA,
CD62L+) and effector memory cells (CD62L, CD45RA) by a cell
sorter (MoFlo, Dako Cytomation). The purity of sorted naïve and
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either used for gene expression analysis immediately or incubated
at 5% O2, with anti-CD3/28-coupled beads at a cell:bead ratio of 1:1
in human culture media, and harvested at the indicated time for
analyses of mRNA. In addition, the culture supernatant was col-
lected for cytokine protein analysis.
For isolation of naïve and memory CD8 T cells from cryopre-
served PBMCs of human adults, PBMCs were thawed in a 37 C
water bath, washed and resuspended in RPMI. Naïve and memory
(Tcm + Tem) CD8 T cells were isolated by a cell sorter (MoFlo, Dako
Cytomation) using the following staining: Viability dye (e506),
CD8+, Naive (CD45RA+, CD28+), and memory (CD28+ ). The purity
of sorted naïve and memory CD8 T cells was >96%.2.4. Gene expression analysis by microarray
Genome-wide gene expression analysis was performed on NE-
treated and untreated CD8 Tcm cells before and after anti-CD3/
CD28 beads stimulation (24 and 72 h) using Agilent’s whole gen-
ome array (SurePrint G3 Human GE 8  60 K V2 Microarray Kit,
Agilent Technologies). Three biological repeated samples were
used for the resting and 24 h time points, and two biological
repeated samples for 72 h were used. Each sample consisted of
pooled RNA from 3 different donors, based on the manufacturer’s
instruction. Brieﬂy, RNA was isolated from cells (RNeasy Mini Kit,
Qiagen) and the integrity and quality of the RNA was tested using
the Bioanalyzer Chip (Agilent).
Next, a two-color microarray-based gene expression analysis of
60,000 genes/transcripts was conducted according to the manu-
facturer’s instructions. We started with 100 ng of total RNA of
the sample and human universal reference RNA for labeling using
the Low Input Quick Amp Labeling Kit based on the manufacturer’s
instructions. The labeled probes were quantiﬁed by NanoDrop ND-
1000 UV–vis Spectrophotometer version 3.2.1 (G4851B, Agilent).
Samples were hybridized onto whole human genome 8  60 K
array slides for 17 h at 65 C in a rotator oven, followed by washing
with appropriate Wash Buffers (Agilent). Hybridization signals
were extracted via the Agilent Feature Extraction Software.
Two-color microarray data was ﬁrst extracted from the Agilent
reader, and was log-normalized relative to the reference color.
Data was batch normalized and signiﬁcant outliers were ﬁltered
using custom ‘perl’ scripts. Determination of the most signiﬁcantly
different gene ontology (GO) groups was done through Broad Insti-
tute’s Gene Set Enrichment Analysis (GSEA) tool (Mootha et al.,
2003; Subramanian et al., 2005). We utilized the Biological Pro-
cesses sub-category of the GO groups provided by Broad Institutes’
Molecular Signature Database. Groups were deemed signiﬁcant at
a FDR q-value of 0.25 or below. Genes of interest for each group
were extracted based on the core enrichment value provided by
GSEA. The pre-activation time point was studied alone; however,
the post-activation 24 h and 72 h time points were combined into
a single group during GSEA analysis. The entire microarray data set
was deposited in the GEO database (GSE64635).2.5. Quantitative RT-PCR of mRNA of human donors
The procedure for real time quantitative PCR (RT-qPCR) was
described previously (Araki et al., 2009). Brieﬂy, RNA was isolated
using the RNeasy Mini Kit with Qiacube (Qiagen) and cDNA was
synthesized with oligo-dT and random hexamers (Life Technolo-
gies) with 60 ng of RNA. Primer sequences can be found in the Sup-
plementary material (Supplementary Table 3). The mRNA levels
were determined by quantitative RT-PCR using 2 SYBR Green
PCR Master Mix (Fisher Scientiﬁc) and normalized to a lymphocyte
housekeeping gene, acyl-Coenzyme A oxidase 1 (ACOX1), asdescribed previously (Araki et al., 2009). PCR was performed on
7900HT Fast Real-Time PCR System (Applied Biosystems).2.6. Measurement of cytokine protein by ELISA
Culture supernatants from CD8 T cell subsets were collected
before, 24 h, and 72 h after anti-CD3/CD28 stimulation. The
amount of cytokine proteins was determined by an ELISA kit (ELISA
Max Deluxe Set Human: IL-2, IL-6, MCP-1, IL-1A, TNF, IFN-c, Bio-
legend) according to the manufacturer’s instructions. Concentra-
tions were calculated according to the standard, and normalized
to the number of cells among different samples.2.7. Assay for adrenergic receptor agonist and antagonists
To verify if the ADRB2 is the primary receptor for NE on mem-
ory CD8 T cells, we isolated ADRB2+ and ADRB2 memory CD8 T
cells by a cell sorter using anti-ADRB2 mAb by custom conjugation
with PerCP/Cy5.5, as described in the above section. We also
isolated memory CD8 T cells via a negative immunomagnetic sep-
aration described in Section 2.3 for testing the ADRB2 agonist and
antagonists. The purity of isolated memory CD8 T cells was 82%
(no detectable naïve CD8 or CD4 T cells) and had comparable
changes in cytokine expression by NE and its agonist and antago-
nists when memory CD8 T cells were isolated by a cell sorter (data
not shown).
To further determine that ADRB2 is the primary receptor for NE,
we added Terbutaline (ADRB2 agonist, catalog #T2528, Sigma–
Aldrich) at a concentration of 105 M and incubated for 16 h before
activation. For the antagonist experiments, Nadolol (beta-adrener-
gic receptor antagonist (ADRB), catalog #N1892, Sigma–Aldrich) or
Phentalomine (alpha-adrenergic receptor (ADRA) antagonist, cata-
log #P7547 Sigma–Aldrich) were added at 105 M at the same time
as NE. We did serial dilutions (103, 105 and 108 M) of the ago-
nist and antagonists based on previous reports and found 105 M
to be the most effective dose after titrating the agonist and antag-
onists (data not shown). The treated CD8 T cells were stimulated
with CD3/CD28 antibodies. Treated cells were harvested and the
culture supernatants were collected before and 24 h after activa-
tion for RT-qPCR and ELISA analyses, respectively.2.8. NE measurements in serum
NE was measured in the serum of all donors as described previ-
ously (Eisenhofer et al., 1986). Brieﬂy, peripheral blood was col-
lected after a 15 min rest period and placed on ice until
processed and stored at 80 C (Eisenhofer et al., 1986). When
thawed, NE was measured using standard high-performance liquid
chromatography (HPLC) with electrochemical detection that has
been previously established for simultaneous measurement of
the concentrations of catecholamines; quantiﬁcation of NE was
detected with a triple-electrode system. The designation of
150 pg/mL for the high or low NE level in serum was reached by
averaging the 3 time points donors had their NE levels measured
during a 3 month timeframe and ﬁnding the approximate median
among the donors. NE levels of three measurements were quite
stable as determined by the Spearmen’s rank correlation coefﬁ-
cient (0.735 for time point 1 vs. 2, 0.620 for time point 1 vs. 3,
and 0.694 for time point 2 vs. 3) and by a Kruskal–Wallis test for
the differences between the three time points (p = 0.815). Utiliza-
tion of these samples and the primary investigation where the
samples originated was approved by the Internal Review Board
at the National Heart Lung and Blood Institute (NHLBI), NIH and
the University of Pennsylvania.
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Data are expressed as the mean ± SEM and signiﬁcance was
assessed using the paired Student’s t-test. p < 0.05 was considered
signiﬁcant.
3. Results
3.1. ADRB2 is highly expressed in the memory subsets compared to the
naïve subset of CD8 T cells
Previous studies have found that ADRB2 is heterogeneously
expressed on different immune cells (Anstead et al., 1998; Kohm
and Sanders, 2001; Sanders, 2012), yet the expression of ADRB2
on CD8 T cell subsets is not known. We ﬁrst assessed the surface
expression of ADRB2 by ﬂow cytometry on the 3 subsets of CD8
T cells (Tn, Tcm and Tem) in the PBMCs of healthy human adults
(Fig. 1A). We found that the memory populations (Tcm and Tem)
of CD8 T cells expressed a signiﬁcantly higher percentage (40%)
of ADRB2 compared to the Tn population (10%) (Fig. 1B). Further-
more, memory CD8 T cells also expressed signiﬁcantly more
ADRB2 on average compared to Tn cells as measured by MFI with
ﬂow cytometry (Fig. 1C). To further determine if ADRB2 expression
is regulated by transcription, we assessed the mRNA level of
ADRB2 in Tn, Tcm and Tem and found greater expression (0.61-fold
higher) in memory CD8 T cells (Tcm and Tem) compared to Tn cells
(Fig. 1D). Together, our ﬁndings show that ADRB2 is highly
expressed in memory CD8 T cell populations compared to the Tn
population.A
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The effect of NE on the expression of several cytokines in CD8 T
cells has been reported (Kalinichenko et al., 1999; Sanders, 2012;
Strell et al., 2009), but a genome-scale assessment of NE-induced
changes in CD8 T cells has not been conducted. We focused on
Tcm cells because of their critical role in the recall response for
adaptive immunity and their high level of ADRB2 expression. To
determine the overall impact of NE on human CD8 T cells, we con-
ducted a genome-wide analysis of gene expression changes in CD8
Tcm cells after NE exposure using a microarray. CD8 Tcm cells were
isolated from healthy adults and treated with NE for 16 h before
stimulation with antibodies against CD3 and CD28 (anti-CD3/
CD28), and harvested before 24 and 72 h after stimulation for gene
expression analyses. Genes with the greatest degree of changes
after NE treatment were identiﬁed (Supplemental Table 4).
A functional assessment using GSEA of altered gene expressions
by NE treatment revealed important biological and immunological
functions, including regulation of cell differentiation, cell cycle pro-
cess and MAPK activity (Fig. 2A). Among the NE induced genes that
were identiﬁed based on GSEA and fold changes, we focused on the
inﬂammatory cytokines and relied on RT-qPCR method to conﬁrm
and extend our analysis to other inﬂammatory cytokines in all CD8
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exhibited a similar upregulation of IL1A and IL6, while Tn cells
did not show a signiﬁcant difference in expression between NE
treated and untreated cells (Fig. 2B). Both IL1A and IL6 have multi-
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172 C. Slota et al. / Brain, Behavior, and Immunity 46 (2015) 168–1792000). In addition, several chemokines related to the inﬂammatory
and chemoattraction processes were also upregulated in the NE
treated cells, including CXCL1, CXCL2, CXCL3 and CCL2, as deter-
mined by the RT-qPCR method (Fig. 2C).Next, we assessed whether the NE induced changes observed at
the mRNA level correlate with the protein level. We then measured
protein levels of selected cytokines and chemokines in the culture
supernatant of the memory CD8 T cells by ELISA. Since NE treated
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did not further investigate this population. A similar increase in the
protein levels of IL-1A and CCL-2, but not IL-6 was observed
(Fig. 2D). Together, these results demonstrate that memory CD8
T cells were more susceptible to the effects of NE than the naïve
CD8 T cell subset, and suggest that NE exposure induces a pro-
inﬂammatory state in memory CD8 T cells.
3.3. Activation induces greater expression of inﬂammatory cytokines
and chemokines in NE treated memory CD8 cells
We next asked what impact NE would have on memory CD8 T
cells in response to activation and again found several cytokines
and chemokines signiﬁcantly upregulated (top 100 most altered
genes after activation are identiﬁed in Supplemental Table 5).
Using GSEA, we identiﬁed the altered biological and immunologi-
cal functions in NE-treated Tcm CD8 cells (Fig. 3A). We again
focused on the inﬂammatory cytokines and relied on RT-qPCR
method to conﬁrm and extend our analyses to other inﬂammatory
cytokines in memory CD8 T cells (Tcm and Tem).
Among the altered expressed genes, IL6, CXCL2, CXCL3, and CCL2
were upregulated with NE treatment before activation and
remained upregulated after activation compared to controls
(Fig. 3B). Furthermore, two pro-inﬂammatory cytokines (TNF and
IL36G) and a chemokine (CCL8) were upregulated in NE treated
memory CD8 T cells only after activation (Fig. 3C). We examined
TNF speciﬁcally since it is a well-known pro-inﬂammatory cyto-
kine involved in inﬂammatory-related diseases. CCL8, a chemokine
involved in several immune-regulatory and inﬂammatory pro-
cesses, exhibited a similar enhanced expression pattern to TNF,
whereas IL36G, participating in local inﬂammatory responses,
showed an increased enhancement of expression from 24 to 72 h
compared to the control (Fig. 3C).
Protein levels of TNF, IL-6 and CCL-2 in the culture supernatant
correlated with the gene expression changes at 24 and 72 h after
activation (Fig. 3D). We observed an average fourfold increase in
the protein level of TNF compared to a twofold difference in IL-6
and CCL-2. In 5 of the 6 cases, the most signiﬁcant difference in
protein levels between untreated and treated memory CD8 T cells
was observed at 24 h.
3.4. Activation induces lower expression of growth-related genes in NE
treated memory CD8 T cells and consequently reduces activation-
induced expansion of CD8 T cells
In contrast to the enhanced expression of inﬂammatory cyto-
kines in NE-treated memory CD8 T cells before and after stimula-
tion, we also identiﬁed two growth-related cytokines (IL2 and
IFNG) whose expression levels were reduced in NE-treated mem-
ory but not naïve CD8 T cells after stimulation. IL2met both criteria
of the altered gene expression by the microarray and RT-qPCR;
however, IFNG did not meet the criteria of our microarray, but
was conﬁrmed by RT-qPCR as signiﬁcantly altered with NE treat-
ment (Fig. 4A). IL2 is an important growth factor and IFNG has been
previously shown to promote the growth of memory T cells (Asao
and Fu, 2000; Kryczek et al., 2008; Zhang et al., 1998). The reduced
expressions of IL2 and IFNG were further conﬁrmed at the protein
levels in the culture supernatant of stimulated memory CD8 T cells
(Fig. 4B). These ﬁndings suggest that NE has an immunosuppres-
sive effect on memory CD8 T cells by signiﬁcantly down-regulating
cytokines critical for the proliferation of CD8 T cells.
To determine the impact of the reduced expression of growth-
related cytokines such as IL-2 and IFN-c, we assessed the activa-
tion-induced expansion of memory CD8 T cells and observed a
signiﬁcant reduction in the cell number of NE treated CD8 Tcm
cells 24 h after activation compared to the NE untreated CD8Tcm cells (Fig. 4C). To rule out the potential role of cell death in
the differences in activation-induced expansion, we analyzed cell
viability and found no signiﬁcant difference in the viability of
Tcm cells between NE treated and untreated Tcm cells at baseline,
24 or 72 h after activation (Fig. 4D).
3.5. NE effect on memory CD8 T cells is mediated by ADRB2
NE can bind to other adrenergic receptors aside from the ADRB2
(Ramer-Quinn et al., 1997). To determine if ADRB2 was responsible
for the observed NE effects on memory CD8 T cells, we isolated
ADRB2+ and ADRB2 CD8 memory T cells with a cell sorter. The
effects of NE on the expression of IL1A and IL6 (before activation),
and IL2 and TNF (after 24 h activation) were signiﬁcantly greater in
theADRB2+ than in the ADRB2memoryCD8T cells (Fig. 5A). To fur-
ther determine whether the effects of NE were through ADRB2 but
not ADRB1, we treated resting memory CD8 T cells with an ADRB2
agonist, Terbutaline, and found it induced an indistinguishable level
of changes in mRNA and protein levels of IL1A and IL6 compared to
the NE treated memory CD8 T cells (Fig. 5B and C). We also deter-
mined if NE stimulates the ADRB2 speciﬁcally by exposing memory
CD8T cells toNE in the presence or absence of either the beta-adren-
ergic receptor (ADRB) antagonist (Nadolol) or the alpha adrenergic
receptor (ADRA) antagonist (Phentalomine). Blocking ADRB with
Nadolol abolished the NE effect on IL1A and IL6 but blocking ADRA
with Phentalomine did not have an obvious impact on NE’s effect
on IL1A and IL6 expression (Fig. 5B and C), suggesting NE’s effect
on memory CD8 T cells is primary mediated by ADRB2, but not by
ADRA. We extended the antagonist analysis to activation-induced
changes in gene expression affected by NE and observed a similar
response: Terbutaline mimicked NE’s effect; Nadolol blocked NE’s
effect, and Phentalomine did not block NE’s effect on IL2 and TNF
expression (Fig. 5D and E).
3.6. High blood NE levels are associated with enhanced expression of
inﬂammatory cytokines in memory CD8 T cells
Our in vitro experiments illustrate a previously unknown effect
of NE inducing greater expression of inﬂammatory cytokines in
memory CD8 T cells. We next asked if these ﬁndings would exist
in an in vivomodel by analyzing the relationship of blood NE levels
and inﬂammatory cytokine expressions in memory CD8 T cells in
32 adults participating in a primary investigation examining the
effects of chronic stress on health outcomes. Subjects who partici-
pated in this study had their serum NE level measured at each visit
with a total of 3 measurements over approximately 3 months.
Based on the approximate median of the blood NE levels, we
grouped subjects into two groups: high (>150 pg/mL) and low NE
levels (<150 pg/mL) (Fig. 6A). We isolated memory and naïve
CD8 T cells from frozen PBMCs of these subjects by a cell sorter
and analyzed the expression of inﬂammatory cytokines identiﬁed
from our in vitro work with RT-qPCR and ﬂow cytometry.
We found that IL1A and TNF were signiﬁcantly higher in mem-
ory CD8 T cells of the high NE group than the low NE group,
whereas IL2 was signiﬁcantly lower in memory CD8 T cells of the
high NE group compared to the low NE group (Fig. 6B). We then
measured the protein levels of these 3 cytokines via intracellular
staining with ﬂow cytometry. We found adults in the high NE
group had signiﬁcantly higher percentages of memory CD8 T cells
expressing IL-1A and TNF, but a signiﬁcantly lower percentage of
memory CD8 T cells expressing IL-2 (Fig. 6C).
4. Discussion
Here we conducted a comprehensive assessment of how NE
modulates CD8 T cell subsets by examining ADRB2 expression,
AC
B
D
IL6 CXCL2 CXCL3 CCL2
********* *** *** *** *** *** *** *** *** ***
TNF CCL8 IL36G
************** **
)2
G
OL( l ort no
C/ E
N
) 2
G
OL( l ort no
C/ E
N
0 h 72 h24 h
0 h 72 h24 h 0 h 72 h24 h 0 h 72 h24 h
*** **
** *
TNF
L
m/gn noit art necno
C
0 h 72 h24 h
Te
m
Tc
m
L
m/gn noit art necno
C
CCL-2IL-6
** ***
0 h 72 h24 h
*** **
*** *
*** *** *
0 h 72 h24 h
Control
NE
0
2
4
6
0
2
4
6
0
1
2
0
1
2
0.0
0.1
0.2
0.3
0.4
0.0
0.1
0.2
0.3
0.4
0
2
4
6
Tcm
Tem
0
2
4
6
8
Tcm
Tem
0 h 72 h24 h 0 h 72 h24 h
Functional group Notable Enriched Genes NE-effect NES* FDR q-value 
Inflammatory and Humoral Response CCL22, IL8, CXCL1, CXCL2, CCL2, IL6 Enhanced -2.15 <0.001
Positive Regulation of Cytokine Biosynthethic Process TLR8, EREG, TLR1 Enhanced -1.88 <0.001
Mitosis TPX2, MADL2, CDCA5, CCNA2 Reduced 1.69 0.121
Chromosome segregation TOP2A, NEK6, INCENP, BRCA1 Reduced 1.69 0.091
*NES=Normalized Enrichment Score
Fig. 3. Activation induces greater expression of inﬂammatory cytokines and chemokines in norepinephrine treated memory CD8T cells. (A) Relevant gene ontology (GO)
groups extracted from GSEA comparison between treated and untreated CD8 Tcm cells after activation. These groups had signiﬁcant FDR q-values (<0.25), and representative
genes were chosen from the set of core enriched genes, also derived from GSEA. (B) Signiﬁcantly increased inﬂammatory cytokines and chemokines (mRNA) in NE treated CD8
T cells before and activation. Results are presented as a ratio (NE/Control) on a log2 scale for 0, 24, and 72 h in Tcm and Tem cells (N = 6–14). (C) Signiﬁcantly increased
inﬂammatory cytokines and chemokines (mRNA) in NE treated CD8 T cells only after activation. Data is presented as a ratio (NE/Control) on a log2 scale for 0, 24, 72 h in Tcm
and Tem cells (N = 6–14). (D) Protein level expression of selected cytokines and chemokines at 0, 24, 72 h after activation in untreated (control) and NE treated Tcm and Tem
cells. Data is presented as the concentration (ng/mL) (N = 6–12).
174 C. Slota et al. / Brain, Behavior, and Immunity 46 (2015) 168–179transcriptional and protein level alterations, and activation-
induced expansion in both an in vitro condition using a physiolog-
ical relevant concentration of NE, and in an in vivo setting using a
study cohort with known serum NE levels. Our results demonstratethat ADRB2 is highly expressed in memory CD8 T cells, revealing
the preferential effect of NE on memory CD8 T cells. Furthermore,
we found that NE induces inﬂammatory cytokine production while
simultaneously reducing production of growth-related cytokines,
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T cells. Ultimately, this indicates a two-sided effect of NE on mem-
ory CD8 T cells. Finally, we show that a high serum concentration
of NE is associated with a high expression of inﬂammatory cyto-
kines and a low expression of growth-related cytokines in the
memory CD8 T cells of stressed adults. NE’s preferential impact
on memory CD8 T cells may help improve our understanding of
the mechanisms of NE in chronic stress-associated immune-
related disorders such as viral and bacterial infections (Farias
et al., 2011; Kemeny and Schedlowski, 2007).
ADRB2 is known to be expressed differently in different type of
cells within PBMCs and believed to be the main receptor for NE(Sanders, 2012). Our study extends these ﬁndings by showing
ADRB2 is differentially expressed on naïve and memory CD8 T
cells. Fewer naïve CD8 T cells express ADRB2, but signiﬁcantly
more antigen-experienced memory CD8 T cells express ADRB2.
Furthermore, ADRB2 is signiﬁcantly more abundant on memory
than naïve CD8 T cells. Previous studies also show that ADRB2
plays a critical role in regulating the immune function of lympho-
cytes (Anstead et al., 1998; Bonneau et al., 1990; Khan et al., 1986;
Mills et al., 2004, 1997). Here, we demonstrate memory CD8 T cells
expressing ADRB2 respond to NE, but memory CD8 T cells that are
ADRB2 negative do not respond to NE. The effect of NE on memory
CD8 T cells is primarily through ADRB2, as supported by the results
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nist was able to mimic the changes induced by NE at the mRNA and
protein level. The alpha antagonist showed no effect on NE-
induced changes in expression of the four cytokines tested, while
the beta adrenergic antagonist almost completely blocked NE’s
effect on these cytokines. Our ﬁndings suggest that ADRB2 is the
primary receptor for NE, and ADRA does not play a measurable role
in NE-induced memory CD8 T cell changes. Our ﬁndings demon-
strate for the ﬁrst time that ADRB2 expression in CD8 T cells is dif-
ferentially regulated and the impact of NE is preferentially on
memory CD8 T cells. Further studies need to be conducted to pro-
vide further insight into the mechanisms behind altered cytokine
production in memory CD8 T cells following NE binding to the
ADRB2.
Chronic stress and inﬂammation is intricately linked via a net-
work of interactions mediated by neurotransmitters and hormones
(Carlson et al., 1989; Levite, 2000; Straub et al., 1998). NE is also
implicated in the inﬂammatory response through a variety of path-
ways, one of them being the regulation of IFN-c production in
immune cells (Dhabhar et al., 2012; Dimsdale et al., 1994;
Mausbach et al., 2005; Sperner-Unterweger et al., 2014). However,
the global scope and the type of T cell subsets that respond to NE
have not been previously addressed. Our global gene expression
analysis of memory CD8 T cells before and after activation reveals
some unexpected and rich ﬁndings of NE-induced production of a
large panel of inﬂammatory cytokines by memory CD8 T cells.
Interestingly, we found NE induced an inﬂammatory state in mem-
ory CD8 T cells even before the cells were activated. Cytokines
genes such as IL6 and TNF play an important role in the pro-inﬂam-
matory response as well as a variety of other immune responses.
Chemokines discussed such as CCL2, CXCL1 and CXCL3 also mediate
inﬂammatory responses as well as having important chemotactic
activity for lymphocyte and monocyte migration. After activation,
some of the same inﬂammatory cytokines and chemokines were
still signiﬁcantly increased as well as some new inﬂammatory
markers.
Previous studies have shown the inhibitory impact of NE on
immune cells (Kalinichenko et al., 1999; Kohm and Sanders,2000, 2001; Lang et al., 2003; Malarkey et al., 2002; Ramer-
Quinn et al., 2000; Swanson et al., 2001), including CD8 T cells
and the alteration in IFN-c and IL-2 production (Strell et al.,
2009; Torres et al., 2005; Wahle et al., 2006). Our study supports
these ﬁndings by showing a reduction in the expression of IFN-c
and IL-2 in NE treated memory CD8 T cells. The decrease in IL-2
and IFN-c production may contribute to the modest decrease in
cell number found in NE treated cells after stimulation, which
may play a role in altering the proliferation of NE treated compared
to untreated memory CD8 T cells. However, the precise intracellu-
lar pathways leading to these transcriptional and protein changes
requires further investigation.
Findings from our study of CD8 T cell subsets may help explain
the conﬂicting ﬁndings of previous studies looking at the effect of
NE on immune cells to be immune suppressive, immune-enhanc-
ing, or null (Dhabhar et al., 2012; Kin and Sanders, 2006; Strell
et al., 2009). By studying immune cells in PBMCs rather than spe-
ciﬁc cell types, or even subsets (naïve or memory), the actual
effects of NE on a subset of lymphocytes can be masked by the lar-
ger group of other types of immune cells. Future studies will ben-
eﬁt from utilizing deﬁned types of immune cells and their subsets
to draw out the impact of NE on these cells. Memory CD8 T cell
sensitivity to NE may have clinical relevance since memory cells
are responsible for recall immune responses as opposed to naïve
cells that ﬁght off new challenges. An individual with high levels
of NE may be more compromised in terms of ﬁghting off recall
infections rather than new antigenic challenges.
Compared to our in vitro ﬁndings under controlled conditions,
in vivo changes are likely inﬂuenced by multiple factors. It is there-
fore reassuring to ﬁnd that some inﬂammatory-related cytokines
and chemokines in adults with high blood levels of NE are also ele-
vated in memory CD8 T cells compared to adults with low blood
levels of NE; these ﬁndings are similar to the inﬂammatory
response we observed in vitro. We also examined other cytokines
and chemokines (CCL2, IFNG, IL6, CXCL1, and CCL8) but did not ﬁnd
signiﬁcant differences between the high and low NE groups. There
was also no difference in ADRB2 expression between the high or
low NE groups in lymphocytes, Tn, or Tm cells (Supplementary
178 C. Slota et al. / Brain, Behavior, and Immunity 46 (2015) 168–179Fig. 2). It is important to note that the effects observed in vivo could
be a result of a combined inﬂuence from hormones and neuro-
transmitters including NE directly or indirectly (Straub et al.,
2000, 1998). Nevertheless, NE appears to play an important role
in modulating CD8 T cell function, particularly in memory cells.
The impact of chronic stress on immune function is undoubt-
edly complex. More work needs to be done to better understand
the impact of NE on CD8 T cells as well as on other types of lym-
phocytes such as CD4 and B cells. Investigating the effect of NE
under deﬁned in vitro conditions and some suitable in vivo settings
will help to elucidate the role of NE in modulating immune func-
tion. Future work should also focus on the clinical implications of
high NE levels, particularly on immune health outcomes as well
as interventions to alleviate the effects of stress on the immune
system.
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